2024-11-19 13:12:34,315 - INFO - Question: Will Bausch Health, Inc., file for bankruptcy before January 1, 2025?
2024-11-19 13:12:34,315 - INFO - News articles for question 30196:
Here are the relevant news articles:

**LMR Partners LLP Takes Position in Bausch Health Companies Inc. (NYSE:BHC)**
LMR Partners LLP purchased a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) in the 3rd quarter, valued at approximately $3,264,000. Several other institutional investors and hedge funds have also added to or reduced their stakes in BHC. A number of research firms have recently weighed in on BHC, with Piper Sandler downgrading the stock from a 'neutral' rating to an 'underweight' rating and dropping their target price from $9.00 to $3.00. The stock currently has an average rating of 'Hold' and an average target price of $7.75. EVP Seana Carson sold 13,370 shares of the firm's stock in a transaction that occurred on Friday, September 6th, valued at $83,027.70. Shares of NYSE BHC opened at $8.38 on Tuesday. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -17.46 and a beta of 0.74. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $11.46.
Original language: en
Publish date: November 19, 2024 10:40 AM
Source:[Market Beat](https://www.marketbeat.com/instant-alerts/lmr-partners-llp-takes-position-in-bausch-health-companies-inc-nysebhc-2024-11-19/)

**CareMax Becomes Latest Health System to File for Bankruptcy**
CareMax Inc., a Miami-based health system catering to elderly patients, has filed for bankruptcy in Texas. The company listed assets of between $100 million and $500 million and liabilities between $500 million and $1 billion. CareMax has reached an agreement with Revere Medical to sell its management services organization, which supports care for approximately 80,000 Medicare beneficiaries. The company also intends to disclose the terms of a proposed agreement with a third-party buyer for its operating clinic business. CareMax has filed motions to maintain business-as-usual, including patient care and paying wages without interruption. The company had previously warned of a potential Chapter 11 filing due to creditor and landlord relief issues. CareMax's stock price has plummeted to $1.39 from a high of over $500 three years ago, with a net loss of $170.6 million reported for the second quarter of 2024.
Original language: en
Publish date: November 18, 2024 01:04 AM
Source:[Yahoo! Finance](https://finance.yahoo.com/news/caremax-becomes-latest-health-system-000512098.html)

**Medical services provider CareMax files for Chapter 11 restructuring**
CareMax, a medical services provider operating 56 medical centers in Florida, Texas, Tennessee, and New York, filed for Chapter 11 bankruptcy in Texas on Sunday. The company listed debts of $693 million and assets of $390 million. This move follows other healthcare group bankruptcies this year, including Steward Health Care's bankruptcy in May. CareMax had acquired Steward's Medicare value-based business in 2022 for $25 million in cash and 23.5 million shares of its stock. The company plans to pursue a sale or other transactions for its management services organization and core centers assets. 'It's a challenging time for the healthcare industry,' said a spokesperson, but no further details were provided. CareMax shares have fallen 89% year-to-date, closing at $1.68 on Friday.
Original language: en
Publish date: November 17, 2024 03:59 PM
Source:[kwsn.com](https://kwsn.com/2024/11/17/medical-services-provider-caremax-files-for-chapter-11-restructuring/)

**Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance By Investing.com**
Bausch Health Companies Inc. (BHC) has shown a mix of strong financial performance and ongoing challenges, particularly related to its debt structure. The company reported revenues of $2.51 billion in Q3 2024, a 12% year-over-year increase and 9% organic growth. However, its high debt leverage of approximately 7x and upcoming debt maturities in 2025-2026 pose significant risks to the company's future growth prospects. BHC's management has been actively evaluating options to maximize the value of its equity stake in Bausch+Lomb (BLCO) for shareholders, which could lead to significant upside for the company. Despite these efforts, the company faces risks from potential generic competition, particularly for its key products like Xifaxan, and its high debt levels may limit its ability to invest in research and development. Successful execution of BHC's strategic initiatives could significantly boost shareholder value, but the company's debt issues and the possibility of bankruptcy proceedings could delay or even halt this process.
Original language: en
Publish date: November 05, 2024 03:32 AM
Source:[Investing.com UK](https://uk.investing.com/news/company-news/bausch-health-companies-swot-analysis-debt-woes-cloud-strong-q3-stock-performance-93CH-3770981)

**Bausch Health Companies (NYSE:BHC) Enters into Second Incremental Amendment with Bausch + Lomb**
Bausch Health Companies Inc. announced that its subsidiary, Bausch + Lomb Corporation, has entered into the Bausch + Lomb Second Incremental Amendment, a credit and guaranty agreement amendment dated November 1, 2024. The amendment involves new term loans of $400,000,000, known as the Bausch + Lomb Second Incremental Term Loans, with a maturity date of May 10, 2027. The borrowed amount will be used to repay outstanding revolving loans and for general corporate purposes. The amendment offers flexibility in interest rates, allowing the borrower to select between a base rate or term SOFR, along with applicable margin rates. The basic terms of the Bausch + Lomb Credit Agreement remain intact unless superseded by this amendment. The creation of these financial obligations further solidifies Bausch Health Companies' commitment to financial strategies and growth initiatives.
Original language: en
Publish date: November 03, 2024 01:22 PM
Source:[modernreaders.com](https://www.modernreaders.com/news/2024/11/03/bausch-health-companies-nysebhc-enters-into-second-incremental-amendment-with-bausch-lomb.html)

**Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher  on Earnings Beat**
Bausch Health Companies Inc. (NYSE:BHC) stock rose 8.7% during mid-day trading on Thursday after the company reported better-than-expected earnings. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.09. Several equities research analysts have commented on the stock, with some dropping their price objectives and others upgrading their ratings. According to MarketBeat, the stock currently has a consensus rating of 'Hold' and a consensus target price of $7.33. Insiders own 8.12% of the company's stock, and institutional investors own 78.65%.
Original language: en
Publish date: October 31, 2024 02:43 PM
Source:[Market Beat](https://www.marketbeat.com/instant-alerts/nyse-bhc-percent-advance-2024-10-31/)

**Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation (NYSE:BHC)**
Bausch Health Companies Inc. published a slide deck in conjunction with their 2024 Q3 earnings call. Seeking Alpha's transcripts team developed the transcript-related projects, including thousands of quarterly earnings calls per quarter. The purpose of this profile is to share new transcript-related developments with readers.
Original language: en
Publish date: October 31, 2024 01:26 AM
Source:[Seeking Alpha](https://seekingalpha.com/article/4731250-bausch-health-companies-inc-2024-q3-results-earnings-call-presentation)

**Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript**
Bausch Health Companies, Inc. (BHC) held its Third Quarter 2024 Earnings Call, with Thomas Appio, Chief Executive Officer, and JJ Charhon, Chief Financial Officer, participating. The presentation included forward-looking information, and the company reminded listeners to read the disclaimer at the beginning of the presentation. Bausch Health uses non-GAAP financial measures to help investors understand its operating performance, but notes that these measures may not be comparable to those used by other companies.
Original language: en
Publish date: October 31, 2024 01:22 AM
Source:[Seeking Alpha](https://seekingalpha.com/article/4731247-bausch-health-companies-inc-bhc-q3-2024-earnings-call-transcript)

**Conn's Inc. Files for Bankruptcy and Announces Store Closures**
Conn's Inc., a US-based home goods and furniture chain with over a century of history, has filed for bankruptcy and begun closing its stores. The company has announced the closure of over 70 locations in 13 states. Additionally, around 40 locations of W.S. Babcock LLC, which was acquired by Conn's Inc. in late 2023, will also be affected. According to the company, the bankruptcy filing under Chapter 11 is a strategic move to restructure its finances and operations, allowing it to better manage its financial obligations. Conn's Inc. has confirmed the news and added a section to its website with detailed information on the closure, including a list of affected stores and answers to frequently asked questions.
Original language: es
Publish date: October 30, 2024 11:42 PM
Source:[LaPatilla.com](https://www.lapatilla.com/2024/10/30/famosa-cadena-centenaria-de-eeuu-se-declara-en-bancarrota-y-cerrara-casi-un-centenar-de-locales/)

**Bausch Health Companies Inc.: Bausch Health Announces Third Quarter 2024 Results**
Bausch Health Companies Inc. announced its third quarter 2024 financial results, showing a sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP). The company reported consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP) basis. Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP) was $909 million, up 10%. The company raised its full-year 2024 guidance, with current guidance for consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) being $9.500 - $9.675 billion and $3.275 - $3.375 billion, respectively. The company also announced the approval and launch of CABTREO in Canada and the submission of draft protocols for Phase 3 trial addressing moderate- to severe- ulcerative colitis patients.
Original language: en
Publish date: October 30, 2024 08:33 PM
Source:[FinanzNachrichten.de](https://www.finanznachrichten.de/nachrichten-2024-10/63676730-bausch-health-companies-inc-bausch-health-announces-third-quarter-2024-results-200.htm)

**Bausch Health Announces Third Quarter 2024 Results**
Bausch Health Companies Inc. announced its third quarter 2024 financial results, showing a 10% increase in Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) to $909 million. The company reported a 12% increase in total consolidated reported revenues to $2.51 billion, with a 9% increase on an organic basis. The Salix segment reported a 5% increase in revenues, while the International segment reported a 6% increase. The Solta Medical segment reported a 35% increase in revenues, and the Bausch + Lomb segment reported a 19% increase. The company also raised its consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) guidance. 'Our team at Bausch Health continued to execute against our commitments in the third quarter, delivering a sixth consecutive quarter of year-over-year growth in both revenue and Adjusted EBITDA,' said Thomas J. Appio, Chief Executive Officer. 'This was accomplished while we continued to advance our R&D pipeline, including the approval and launch of CABTREO in Canada. These results reflect the strength of our diverse and robust portfolio of products, both geographically and across therapeutic areas.'
Original language: en
Publish date: October 30, 2024 08:20 PM
Source:[wallstreet:online](https://www.wallstreet-online.de/nachricht/18651444-bausch-health-announces-third-quarter-2024-results)

**Conn's Inc. Files for Bankruptcy and Closes Over 70 Stores**
Conn's Inc., a home goods and furniture chain with over a century of history, has filed for bankruptcy and begun closing its stores. The company has announced the closure of over 70 locations in 13 states, with more than 70 Conn's HomePlus stores expected to close by the end of 2024. The company also acquired W.S. Babcock LLC in late 2023, and approximately 40 of its locations will also be affected. The company's bankruptcy filing is part of a restructuring effort to address its financial obligations. According to the company, they are selling all their inventory at discounted prices, stating, 'We are selling all our inventory at discounted prices.' The company's financial situation has been complicated, with a net loss of $76.89 million in the same period last year, and a 7.8% decrease in annual total income compared to the previous year, reaching $1.2 billion.
Original language: es
Publish date: October 30, 2024 07:04 PM
Source:[La Nacion](https://www.lanacion.com.ar/estados-unidos/adios-a-una-famosa-cadena-centenaria-de-estados-unidos-se-declara-en-quiebra-y-cierra-70-locales-nid30102024/)

**Bausch Health Companies (BHC) Scheduled to Post Earnings on Wednesday**
Bausch Health Companies (NYSE:BHC) is set to announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to report earnings of $1.05 per share for the quarter. The company has set its FY 2024 guidance at EPS. Bausch Health Companies has a market capitalization of $2.96 billion and a P/E ratio of -6.60. The company's 50-day simple moving average is $7.31 and its 200-day simple moving average is $7.04. Analysts have given Bausch Health Companies an average rating of 'Hold' and an average price target of $7.33. The company operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
Original language: en
Publish date: October 29, 2024 04:14 AM
Source:[dispatchtribunal.com](https://www.dispatchtribunal.com/2024/10/29/bausch-health-companies-bhc-scheduled-to-post-earnings-on-wednesday.html)

**Bausch Health Companies (BHC) Set to Announce Quarterly Earnings on Wednesday**
Bausch Health Companies (NYSE:BHC) is set to announce its quarterly earnings on Wednesday, October 30th. Analysts expect the company to report earnings of $1.05 per share. The company has set its FY 2024 guidance at EPS. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The stock has a market capitalization of $2.93 billion, a P/E ratio of -6.54 and a beta of 0.77. EVP Seana Carson sold 13,370 shares of the company's stock in a transaction dated Friday, September 6th, valued at approximately $2,702,579.58. 8.12% of the stock is currently owned by insiders. Analysts have given Bausch Health Companies a 'Hold' rating, with a consensus price target of $7.33. The company operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
Original language: en
Publish date: October 23, 2024 08:56 AM
Source:[Market Beat](https://www.marketbeat.com/instant-alerts/nyse-bhc-earnings-date-2024-10-23/)

**Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags - Apollo Global Management (NYSE:APO), Altus Power (NYSE:AMPS)**
Altus Power AMPS has hired Moelis & Company LLC to explore strategies to boost shareholder value, aiming to complete the process by 2025. Motorsport Games Inc. MSGM is also looking to increase shareholder value via a potential sale or merger to fund the release of Le Mans Ultimate on Sony PlayStation and Microsoft Xbox consoles. In other news, H. Lundbeck A/S acquired Longboard Pharmaceuticals, Inc LBPH for $60 per share in cash, valued at approximately $2.6 billion. Universal Stainless & Alloy Products, Inc. USAP agreed to an all-cash offer by Aperam for $45 per share. Bit Digital Inc BTBT purchased Enovum Data Centers for about CAD$62.8 million ($46 million). Private equity firms TPG and Blackstone placed a joint bid to acquire eye care company Bausch + Lomb BLCO. True Value declared bankruptcy and plans to sell assets to rival Do it Best. According to S&P Global, M&A activity in the U.S. and Canada lagged compared to 2023, with 4,153 deals announced in the third quarter, down 4.3% from the preceding quarter, but up 2% from the third quarter of 2023. Joe Mantone of S&P Global noted that the quarter-over-quarter drop in the number of deals is not surprising given seasonal trends, but the year-over-year increase in deals provides evidence that M&A is recovering.
Original language: en
Publish date: October 21, 2024 06:56 PM
Source:[Benzinga](https://www.benzinga.com/markets/equities/24/10/41437098/deal-dispatch-altus-power-motorsport-games-explore-options-true-value-goes-bankrupt-m-a-activity)

**Health Care Climbs Slightly Amid Mixed Earnings - Health Care Roundup**
Health-care companies saw a slight increase in stock prices despite mixed earnings. CVS Health replaced its top executive and warned that its upcoming earnings will fall short of expectations, causing its shares to drop around 7% in early trading. Bausch Health, on the other hand, rejected recent debt-restructuring proposals from bondholders as it explores the sale of its Bausch + Lomb vision care unit, which could bring in billions of dollars to pay creditors and reward shareholders, according to The Wall Street Journal.
Original language: en
Publish date: October 18, 2024 09:26 PM
Source:[marketscreener.com](https://www.marketscreener.com/quote/stock/BAUSCH-HEALTH-COMPANIES-I-44965075/news/Health-Care-Climbs-Slightly-Amid-Mixed-Earnings-Health-Care-Roundup-48112203/)

**Will an Eyecare Company Be at the Center of the Yearâ€™s Biggest PE Deal?**
Bausch + Lomb, a leading contact lens supplier, has sparked interest from private equity giants TPG and Blackstone for a potential joint bid to take the company private. This move may be the biggest PE deal of the year, with a potential sale price of $11.5 billion, including debt. The company has been struggling due to its parent company, Bausch Health, which has a $21 billion debt load and is facing potential bankruptcy. A sale to PE could help Bausch Health shore up its balance sheet, as creditors have warned that a spin-off of Bausch + Lomb could cut off the parent company from a key revenue source. Shares of Bausch + Lomb have climbed 18% in the past month amid rumors of a private equity sale, and the company recently received approval from the US FDA for its enVista Envy full range of vision intraocular contact lenses.
Original language: en
Publish date: October 14, 2024 10:40 PM
Source:[thedailyupside.com](https://www.thedailyupside.com/industries/healthcare/will-an-eyecare-company-be-at-the-center-of-the-years-biggest-pe-deal/)

**Bausch Health Companies (NYSE:BHC) Shares Gap Up   - Should You Buy?**
Bausch Health Companies Inc. (NYSE:BHC) shares gapped up on Monday, opening at $8.37 after previously closing at $7.95. The company has been the subject of several research reports, with Piper Sandler downgrading shares from 'neutral' to 'underweight' and lowering their price objective from $9.00 to $3.00. Royal Bank of Canada decreased their price objective from $10.00 to $8.50 and set a 'sector perform' rating. Insiders own 8.12% of the company's stock, with EVP Seana Carson selling 13,370 shares on September 6th. Several large investors have modified their holdings of the business, including Vanguard Group Inc. and Natixis. Bausch Health Companies operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
Original language: en
Publish date: October 14, 2024 05:30 PM
Source:[Market Beat](https://www.marketbeat.com/instant-alerts/nyse-bhc-gap-up-2024-10-14/)

**TPG, Blackstone bid for Bausch + Lomb in potential $14 billion deal**
Private equity firms TPG and Blackstone are teaming up to bid for Bausch + Lomb in a potential $14 billion deal, managed by Goldman Sachs. The sale aims to address disputes related to Bausch Health's large debt. Bausch + Lomb is expected to generate significant revenue from its contact lenses and eye care drugs. According to sources, offers are likely to value Bausch + Lomb at an enterprise value between $13 billion and $14 billion, translating to up to $25 per share. The company closed Friday trading at $19.47 per share. Goldman Sachs is managing the sale process to resolve tensions between Bausch Health's shareholders and creditors. Formal bids are expected by the end of the month, though sources indicated that there is no certainty that a deal will be finalized. 'The spin-off of Bausch + Lomb has been stalled due to concerns that losing its more profitable subsidiary could leave Bausch Health insolvent, given its $21 billion debt load,' said a source. Bausch Health faces $10 billion in debt maturities before 2027, with a $2.4 billion fixed-rate loan due next year being the most pressing.
Original language: en
Publish date: October 14, 2024 09:25 AM
Source:[Economic Times](https://economictimes.indiatimes.com/news/international/business/tpg-blackstone-bid-for-bausch-lomb-in-potential-14-billion-deal/articleshow/114212563.cms)

**TPG and Blackstone team up to bid for eyecare company Bausch + Lomb**
Private equity groups TPG and Blackstone are teaming up to bid for eyecare company Bausch + Lomb, with a potential deal valued at $13-14 billion, according to people familiar with the matter. The bid comes as Bausch + Lomb's parent company, Bausch Health, is struggling with a $21 billion debt pile and has been put up for sale to resolve an impasse over a separation. TPG already owns ophthalmology company BVI Medical, and Blackstone has expressed interest in buying Bausch + Lomb before it went public in 2022. Formal bids are expected by the end of the month, but it is still possible that a deal may not occur. Bausch + Lomb's chief executive, Brent Saunders, has said that the company is 'a great asset' and that he is 'excited' about the potential sale. However, some creditors, including Apollo Management and Elliott Management, have expressed concerns about the sale and have opposed a spin-off process. 'A sale would allow Bausch Health to pay down its debts and potentially pay a special dividend to shareholders,' said one person familiar with the matter. However, this move would likely rankle creditors.
Original language: en
Publish date: October 14, 2024 09:06 AM
Source:[Financial Times News](https://www.ft.com/content/52aaf972-1f3a-4017-b181-74c3a3c1e6ef)

**Bausch Health Companies (TSE:BHC) Trading Down 1.2%  - What's Next?**
Shares of Bausch Health Companies Inc. (TSE:BHC) traded down 1.2% on Wednesday, with a low of C$10.79 and a closing price of C$10.90. The company's debt-to-equity ratio is 7,583.76, and its market cap is C$4.00 billion. Raymond James raised shares of Bausch Health Companies to a 'hold' rating in a research note on July 10th. The company's fifty day moving average is C$8.92 and its two-hundred day moving average is C$10.00. Analysts forecast that Bausch Health Companies Inc. will post 5.5472637 EPS for the current year. 11.28% of the stock is currently owned by company insiders.
Original language: en
Publish date: October 10, 2024 04:58 AM
Source:[Market Beat](https://www.marketbeat.com/instant-alerts/tse-bhc-percent-decline-2024-10-09/)

**Bausch Health Companies Inc. (NYSE:BHC) Short Interest Down 6.2% in September**
Bausch Health Companies Inc. (NYSE:BHC) saw a 6.2% decrease in short interest in September, with 18,600,000 shares sold short as of September 15th. Currently, 5.8% of the shares are sold short. According to research reports, analysts have forecast growth for the company, with a consensus rating of 'Hold' and a consensus target price of $7.33. Institutional investors have recently added to or reduced their stakes in the business, with Salem Investment Counselors Inc. buying a new position in the 1st quarter worth $32,000. Bausch Health Companies has a market cap of $2.99 billion and a price-to-earnings ratio of -6.67. The company has a 12 month low of $3.96 and a 12 month high of $11.46.
Original language: en
Publish date: October 02, 2024 09:10 AM
Source:[kopsource.com](https://www.kopsource.com/2024/10/02/bausch-health-companies-inc-nysebhc-short-interest-down-6-2-in-september.html)

**Investor Alert and Limitation Period: Canadian investors that purchased shares of Bausch Health Companies, Inc. listed on the Toronto Stock Exchange need to act**
Berger Montague (Canada) PC, a Toronto-based law firm, is investigating Bausch Health Companies, Inc. (TSX: BHC) for allegedly failing to disclose material facts about the Opt Out Litigation, a dispute involving 21 investors who opted out of a class action lawsuit. The firm alleges that BHC negligently omitted this information from its quarterly reports, causing the price and value of its shares to drop from $12.03 to $9.42 within the Securities Act ten (10) look-back period. The investigation is ongoing, and investors who purchased BHC's securities between May 2, 2022 and August 1, 2024 are encouraged to contact the firm at [email protected] to learn more or share information.
Original language: en
Publish date: September 30, 2024 07:13 PM
Source:[Cision Canada](https://www.newswire.ca/news-releases/investor-alert-and-limitation-period-canadian-investors-that-purchased-shares-of-bausch-health-companies-inc-listed-on-the-toronto-stock-exchange-need-to-act-804620890.html)

**Bausch Health Companies Inc. (BHC): A Top Pick in Carl Icahn's Stock Portfolio**
Carl Icahn, a renowned investor, has a significant stake in Bausch Health Companies Inc. (NYSE:BHC), a diversified specialty pharmaceutical and medical device company. Icahn's investment firm, Icahn Capital LP, holds a $242.01 million stake in BHC. Despite concerns about the company's financial position, including potential bankruptcy and the sale of its eye care unit, BHC delivered mixed second-quarter results with revenues up 11% yearly to $2.4 billion. However, its consolidated operating income fell to $389 million, and net income attributable to shareholders fell to $10 million. Icahn's investment strategy focuses on unlocking hidden value in undervalued companies, and BHC is one of his top holdings. Nevertheless, Insider Monkey's analysis suggests that AI stocks may hold greater promise for delivering higher returns within a shorter timeframe.
Original language: en
Publish date: September 28, 2024 11:07 AM
Source:[Yahoo](https://finance.yahoo.com/news/bausch-health-companies-inc-bhc-110723983.html)

**Maverick Capital Ltd. Purchases New Shares in Bausch Health Companies Inc. (NYSE:BHC)**
Maverick Capital Ltd. purchased a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 230,431 shares of the company's stock, valued at approximately $1,606,000. Maverick Capital Ltd. owned about 0.06% of Bausch Health Companies as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in shares of Bausch Health Companies by 0.5% in the 4th quarter. Analysts expect that Bausch Health Companies Inc. will post 3.61 EPS for the current fiscal year. Several research firms have issued reports on BHC. Jefferies Financial Group lowered their target price on shares of Bausch Health Companies from $13.00 to $9.00 and set a 'buy' rating on the stock in a research note on Wednesday, August 7th. The company has a market cap of $2.98 billion, a PE ratio of -6.66 and a beta of 0.75. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.
Original language: en
Publish date: September 28, 2024 09:54 AM
Source:[MarketBeat](https://www.marketbeat.com/instant-alerts/nyse-bhc-sec-filing-2024-09-28)

*Generated by AI at [AskNews](https://asknews.app), check out the [API](https://docs.asknews.app) for more information*.
